Output details

Improved in vivo delivery of m-THPC via pegylated liposomes for use in photodynamic therapy

Photodynamic therapy (PDT) is a minimally invasive modality for the treatment of malignant and certain non-malignant lesions, including infections, using photosensitising compounds activated with a fibre-optically coupled laser or an LED. Engineering better tumour targeting strategies is a key objective for improving PDT. This translational study demonstrated that tumour uptake and laser-induced PDT damage could be significantly improved using passively targeted pegylated liposomes incorporating a clinical photosensitiser (mTHPC) compared to its standard clinical formulation, without affecting skin photosensitivity. Since mTHPC is the most widely used second-generation photosensitiser in Europe, these results will have considerable impact on the development of PDT.